In this regard, the release of anti-inflammatory cytokines from skeletal muscle contraction, cortisol elevations, prostaglandin E2, and soluble receptors against TNF and IL-2, and increased mobilization of immunoregulatory leukocyte subtypes may be relevant in attenuating the CRS in COVID-19. The gene discussed is TNF; the disease is COVID-19.